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Preferential atrophy of Type-II muscle fibres occurs in several clinical situations,
including cachexia, muscle disuse, chronic glucocorticoid treatment, remote
neoplasia, and sometimes as an aspect of recent-denervation. For the patient,
the Type-II atrophy itself might be unfavourable (as a glucocorticoid side-
-effect) or favourable (survivalistic via the muscle-alanine liver-gluconeogenesis
pathway in starvation). The cellular mechanisms underlying Type-II fibre atro-
phy are unclear. Myostatin (Mstn) is physiologically a negative regulator of
muscle mass and strength. In this study we evaluated a possible role of Mstn in
Type-II fibre atrophy in human muscle. Mstn and Mstn precursor protein
(MstnPP) were studied in 10-muscle biopsies containing Type-II fibre atrophy
and in 17 disease and normal control muscle biopsies. When comparison was
made with normal control fibres, we found the following: 1) by immunocy-
tochemistry, diffusely increased Mstn/MstnPP in the atrophic Type-II muscle
fibres; 2) by immunoblots, Mstn/MstnPP increased individually; 3) by RT-PCR,
no increase in MstnPP mRNA. In conclusion, our results a) suggest that Mstn/
/MstnPP might play a role in the pathogenic cascade of Type-II muscle fibre
atrophy; b) broaden our previously-described associations of Mstn in human
muscle pathology, and c) could possibly lead to clinical prevention when Type-II
muscle fibre atrophy is unfavourable, for instance in glucocorticoid therapy.
(Folia Morphol 2008; 67: 1–7)
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INTRODUCTION
Selective involvement of muscle fibre types can
occur in various neuromuscular disorders [10]. Pref-
erential atrophy of the Type-II muscle fibres occurs
in cachexia, muscle disuse and chronic treatment
with glucocorticoids [10, 27]. Following experimen-
tal total denervation, guinea-pig Type-II fibres atro-
phy more rapidly than Type-I fibres [17]. With a het-
erogeneous aetiology, the cellular mechanisms
underlying pathogenesis of Type-II muscle fibre
atrophy remain unclear.
Myostatin (Mstn), also called growth and dif-
ferentiation factor-8 (GDF-8), is a member of the trans-
forming growth factor-b (TGF-b) superfamily [13, 26].
Myostatin precursor protein (MstnPP) is a 375 ami-
no acid protein translated from a 3.1 kb mRNA [14].
It was suggested that intracellular processing of
Mstn from MstnPP occurred through furin [16, 24].
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Mstn is a secreted protein considered a normal neg-
ative regulator of muscle growth during develop-
ment and of muscle mass during adulthood [13]. In
mouse models, knocking out the Mstn gene and
overexpressing proteins neutralising Mstn caused an
increase in muscle mass [13]. In cattle and whippet
dogs naturally-occurring myostatin gene mutations
led to significantly increased muscle size [26, 28].
A child with a homozygous Mstn gene mutation
that results in reduced production of Mstn protein
was reported increased muscle bulk and strength [35].
Conversely, mature Mstn protein was report-
ed to have increased in the muscle tissue of pa-
tients with HIV-associated muscle wasting [14], and
increased MstnPP mRNA was reported in muscle
wasting associated with osteoarthritis [31] (these
conditions are associated with Type-II fibre atro-
phy [Engel and Askanas, unpublished]). However, in
some studies, Mstn gene-knockout mice or mice
carrying Mstn gene mutations had muscle weakness,
mitochondria depletion and tubular aggregates, de-
spite their larger muscle mass [1]. Previously, the
question was raised as to whether the larger mus-
cle is better [15].
We recently reported that Mstn and MstnPP were
increased in the muscle fibres of patients with spo-
radic-inclusion body myositis, where it was physi-
cally associated with amyloid-b precursor protein
(AbPP) [37]. Moreover, experimental overexpression
of the AbPP gene in cultured human muscle fibres
resulted in increased MstnPP in these [39]. Our most
recent studies have shown that in ER-stress-induced
cultured human muscle fibres MstnPP and its mRNA
are increased through an NFk-B related mechanism [30].
Accordingly, it appears that various pathological
mechanisms might be involved in Mstn/MstnPP
regulation.
To our knowledge, the association between Type-
II muscle fibre atrophy and Mstn expression has not
previously been tested directly in human muscle. In
the present study we asked whether Mstn is direct-
ly associated with Type-II muscle fibre atrophy and
thus might be contributing to the pathogenetic cascade.
MATERIAL AND METHODS
Patients
We studied diagnostic muscle biopsies that had
been obtained, with the informed consent of the
participants, from 27 patients diagnosed with the
following conditions: Type-II muscle fibre atrophy [10],
peripheral neuropathy [5] and amyotrophic lateral
sclerosis (ALS) [2]. The controls consisted of 10 nor-
mal age-matched muscle biopsies obtained from
patients who, after all the diagnostic studies had
been performed, were deemed not to have a mus-
cle disease. All the patients fell within a 30–83 year
age range; the median age was 64 for Type-II fibre
atrophy patients and 66 for the controls. The diag-
noses were based on clinical and laboratory investi-
gations, including 16-reaction diagnostic histochem-
istry of muscle-biopsies routinely performed in our
laboratory. Type-II fibre atrophy was morphologi-
cally diagnosed with myofibrillar ATPase staining
performed at pH 9.4, with and without pre-incuba-
tion at pH 4.35 [8].
Clinically, four of the patients with Type-II fibre
atrophy had previously been treated with a gluco-
corticoid, while in the other six patients the causes
could not be determined; none was known to have
cancer.
Light-microscopic immunocytochemistry
Immunofluorescence was performed on 10-mm
transverse sections of fresh-frozen muscle biopsies
as described [3, 4, 37], using a well-characterised
rabbit polyclonal antibody against Mstn [14, 30, 32,
37, 39] (Chemicon, Temecula, CA), diluted 1:400.
This antibody is developed against Mstn sequence B
(NMLYFNGKEQIIYGKI) and recognises on immuno-
blots a 28 kDa band of Mstn dimer and a 55 kDa
band of MstnPP [14, 32, 37]. On immunostaining
this antibody recognises both Mstn and MstnPP,
here referred to as staining of Mstn/MstnPP.
To block non-specific binding of an antibody to
Fc receptors, sections were preincubated with nor-
mal goat serum diluted 1:10. The controls for stain-
ing specificity were omission of the primary anti-
body or its replacement with non-immune sera;
these were always negative.
Immunoblots
These were performed as described [37, 38].
Briefly, five 20 mm-thick sections of fresh-frozen
muscle were collected at –25∞C and rapidly homo-
genised on ice in 10 mM Tris-HCl, pH 7.4, containing
150 mM NaCl, 15 mM EDTA, 1 mM phenylmethyl-
sulfonyl fluoride, and protease inhibitor cocktail (Roche
Diagnostic GmBH, Mannheim, Germany). The pro-
tein concentration was measured by the Bradford
method; 20 µg protein in 4X NuPAGE LDS sample
buffer and 10X NuPAGE sample reducing agent were
heat-denatured for 10 min at 70∞C. Subsequently,
they were electrophoretically separated using 12%
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Bis-Tris gel and 1X NuPAGE MES SDS running buf-
fer. After electrophoresis the samples were trans-
ferred to a nitrocellulose membrane for one hour at
30 V in 1X NuPAGE transfer buffer. All reagents were
obtained from Invitrogen (Carlsbad, CA). The nitro-
cellulose membranes were blocked in 5% (wt/vol)
blocking reagent (Amersham Pharmacia Biotech,
Inc., Piscataway, New Jersey) in 1X TBS plus 0.1%
Tween 20, and these were incubated overnight at
4∞C with an anti-Mstn antibody diluted 1:1000.
After being washed, the membrane was incubated
with an appropriate species-specific secondary an-
tibody conjugated to HRP. The blots were developed
using the enhanced chemiluminescence system (Am-
ersham). Protein loading was evaluated by actin
bands visualised with a mouse monoclonal anti-
-actin antibody (Santa Cruz, CA) diluted 1:2000.
Omission of a primary antibody was the control for
reaction specificity. Immunoblots of a recombinant
human Mstn peptide (Research Diagnostic Inc.,
Flanders, NJ) were used as additional controls for
the antibody specificity.
RNA isolation and RT-PCR
Total RNA from muscle biopsies was isolated
as described [29]. Next, 1 mg of RNA was used
in an RT-PCR reaction, utilising OneStep RT-PCR
kit (Qiagen, MA) and primers for MstnPP
(Fw-GTGG-TACCTCATGCAAAAACTGCAACTCTGT,
Rv-ATGGATCCAATCTCATGAGCACCCACAGC) [30, 39],
or GAPDH (glyceraldehade-3-phosphate dehydroge-
nase) [20]. The optimised conditions for MstnPP were
30 min at 50oC and 15 min at 95oC followed by 31
cycles of amplification (94oC for 30 s, 60oC for 30 s,
72oC for 90 s) and a final incubation for 10 min at
72oC. The PCR products were separated on a 1.6%
agarose gel and stained with SYBR Safe DNA gel stain
(Invitrogen, CA). The conditions of the reactions were
experimentally checked to ensure that the signals
were in the linear range of the PCR. The identity of
the products was confirmed by sequencing. The
amount of MstnPP mRNA was quantified by the NIH
Image J 1.310 software and was normalised to the
expression of GAPDH in the same sample to account
for differences in loading between samples.
Statistical analysis
The statistical significance of differences between
groups was determined by Student’s t-test. The lev-
el of significance was set at p < 0.05. All data are
presented as means ± SEM.
RESULTS
In the biopsies with Type-II muscle fibre atrophy,
70–80% of the small fibres were Type-II, which was
revealed by the stainings for two myofibrillar
ATPases (Fig. 1A). The degree and extent of the Type-II
fibre atrophy varied between patients from moder-
ate to prominent. There was no necrosis or phago-
cytosis and no increase of endomysial connective
tissue. There was no recent denervation.
By immunofluorescence atrophic Type-II muscle
fibres were strongly and diffusely immunostained
with the antibody against-Mstn/MstnPP as com-
pared to the normal-sized muscle fibres within the
same section, which were very weakly stained
(Fig. 1B, C). Immunohistochemically, Type-II and
Type-I fibres appeared to have the same amount of Mstn/
/MstnPP in the normal human muscle. Denervated
small angulated muscle fibres in ALS and peripheral
neuropathies did not have increased staining with
that antibody, and some appeared to have decreased
immunoreactivity (not shown).
Immunoblots of muscle biopsies obtained from
control and Type-II fibre atrophy patients revealed
two specific bands of 28 and 55 kDa; the lower band
corresponding to the Mstn dimer and the upper to
MstnPP [32, 37]. Both of those bands were increased
in biopsies with Type-II fibre atrophy (Fig. 2A). Omis-
sion of the primary antibody resulted in no bands
being present (data not shown). Densitometric anal-
ysis (Fig. 2B) revealed that in patients with Type-II
fibre atrophy the amount of Mstn protein was in-
creased 2.2-fold (p < 0.05), while the MstnPP was
increased 3.3-fold (p < 0.01) in comparison with
normal muscle biopsies.
By semi-quantitative RT-PCR the amount of MstnPP
mRNA did not differ significantly between Type-II
fibre atrophy and control biopsies (Fig. 3).
DISCUSSION
For the patient, the Type-II atrophy itself might
be unfavourable (as a glucocorticoid treatment side-
effect) or favourable (survivalistic via the muscle-ala-
nine liver-gluconeogenesis pathway in starvation).
Muscle wasting and decrease in muscle strength
accompany various clinical conditions. Fibre type
distribution is one of the factors determining mus-
cle strength, and prevalence of type Type-II fibres
has been reported to correlate positively with mus-
cle strength [15]. Type-II fibre atrophy is the typical
and sometimes prominent manifestation associat-
ed with muscle wasting of various causes, such as
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cachexia, muscle disuse, glucocorticoid treatment,
and remote neoplasia [9, 10, 27]. Knowledge of the
mechanisms leading to Type-II fibre atrophy could
therefore be of general importance. For example,
many patients with cancer are severely incapacitated
by generalised cachectic muscle weakness. The vari-
ous causes may operate in the same way or in differ-
ent ways, leading to the increased Mstn/MstnPP.
Studies performed on C2C12 mouse and L6 rat
myoblasts in culture, and in rats in vivo, reported
that a glucocorticoid (dexamethasone) increases
MstnPP mRNA, MstnPP and Mstn levels in muscle
[6, 18, 22, 23]. It was suggested that the glucocor-
ticoids induced Mstn gene transcription, possibly
through a glucocorticoid receptor-mediated path-
way [23]. In humans, the Mstn promoter sequence
contains, among other putative muscle growth-fac-
tor response elements, response elements for glu-
cocorticoid [22]. It has also been reported recently
that dexamethasone decreased the mean muscle-
fibre cross-section area by approximately 15% in the
gastrocnemius and tibialis anterior muscles of wild
mice, while in myostatin knock-out mice it did not
exert this effect [12].
In the present study we have shown that, as com-
pared to controls, biopsies with Type-II muscle fibre
atrophy had increased MstnPP and mature Mstn
dimer but did not have increased MstnPP mRNA.
The unchanged MstnPP mRNA might be reflecting
a negative feedback on MstnPP transcription caused
by the increased Mstn and MstnPP protein [11, 24, 40].
Mstn is known to auto-regulate its own synthesis
and processing by stimulating production of a tran-
scription factor, Smad 7, via the interaction between
proteins Smad 2, 3, 4 and the Smad binding-ele-
ment in the Smad 7 promoter. The inducible over-
expression of Smad 7 by Mstn inhibits the MstnPP-
-promoter activity [11], resulting in decreased Mst-
-nPP transcription [40]. Similar to our results was the
finding that in muscle atrophy of older rats, as com-
pared to young rats, Mstn protein was increased,
while the MstnPP mRNA was decreased [5]. It is also
possible that increased Mstn and MstnPP at the pro-
tein level we observed was influenced by translation-
al and/or post-translational modulation of these.
The cause of the increased Mstn/MstnPP in Type-II
atrophic muscle fibres observed by us is not known.
In rodents Mstn is predominantly present in muscle
fibres that express myosin heavy chain isoform IIb
(which are, histochemically, Type-II fibres), as evi-
dent both during development and in mature states
[2, 7, 34]. Our study of normal adult human muscle
Figure 1. A. Representative muscle biopsy, transverse section,
from a patient with Type-II muscle fibre atrophy. In this biopsy
70–90% of the small fibres were Type-II as shown by myofibrillar
ATPase staining (pH 9.4, without acid pre-incubation). ¥700;
B. Staining with antibody against Mstn/MstnPP showed a dif-
fusely increased immunoreactivity in the atrophic muscle fibres;
C. ATPase staining (pH 9.4, without acid pre-incubation) on a par-
allel, but not closely adjacent, section to B confirmed that those
atrophic fibres were Type-II; for clarity some of the corresponding
fibres on B and C have been marked with asterisks. B, C ¥1250.
A
B
C
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shows approximately equal amounts of immunore-
active Mstn/MstnPP in Type-II and Type-I fibres.
Mstn is considered to be a protein secreted by
the muscle fibre, which exerts its influence fairly lo-
cally through extracellular autocrine/paracrine signal-
ling. This is considered to be achieved by its interac-
tion with the activin/TGFb ActIIb receptor on the
muscle fibre [13, 25, 33]. It is suggested that outside
the muscle fibre Mstn is inactivated by being bound
to follistatin, which inhibits Mstn binding to its re-
ceptors on muscle fibres [13, 25]. Within the muscle
fibre, the role of Mstn and that of its intracellular
binding partners remains to be studied.
Our previous data demonstrating increased ex-
pression of Mstn and MstnPP and the co-localisa-
tion and physical association of MstnPP with AbPP
within s-IBM muscle fibres suggested that Mstn/
/MstnPP may exert a novel intracellular influence with-
in human muscle fibres [37]. Studies by others re-
porting that Mstn is present in the nuclei of myo-
tubes derived from the mouse C2C12 cell line sug-
gest that Mstn may play an intracellular role in regu-
lating transcription [2].
CONCLUSION
Our results a) suggest that myostatin and the
myostatin precursor protein may play a novel role
in the pathogenetic cascade leading to Type-II mus-
cle fibre atrophy; b) broaden our previously-
-described associations of myostatin in human
Figure 2. A. Representative immunoblots of homogenates of two biopsies having Type-II muscle fibre atrophy demonstrate stronger
expression of Mstn dimer (28 kDa) and MstnPP (55 kDa) as compared to two normal-control muscle biopsies. The actin band shows the
protein loading in each specimen; B. Densitometric analysis of results from 6 patients versus 6 normal controls, as in A, showed increase
of MstnPP and Mstn (3.3-fold and 2.2-fold, respectively) in Type-II muscle fibre atrophy as normalised to the actin band. Data are indicated
as mean ± SEM. Significance was set at *p < 0.05.
Figure 3. A. Representative agarose gel electrophoresis of products corresponding to MstnPP mRNA and GAPDH mRNA, amplified by the
RT-PCR method; B. Densitometric analysis of results from 5 patients versus 5 controls, as in A, showed that levels of MstnPP mRNA,
normalised to the GAPDH mRNA, were similar in control and patients with Type-II muscle fibre atrophy. All data are indicated as mean ± SEM.
Significance was set at p < 0.05.
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muscle pathology and c) could possibly lead to clin-
ical prevention when Type-II atrophy is unfavour-
able, for instance in glucocorticoid therapy.
Therapeutic methods intended to decrease or
eliminate myostatin, which might possibly be con-
sidered for patients with Type-II fibre atrophy, are
very limited. A previous study reported that treat-
ment with growth hormone significantly decreased
muscle myostatin precursor protein mRNA level in
growth hormone-deficient patients, and in mouse
C2C12 muscle it decreased both myostatin precur-
sor protein mRNA and protein [21]. Whether growth
hormone treatment would benefit Type-II atrophy
patients is not known. Other potentially therapeu-
tic anti-myostatin compounds, such as a) myosta-
tin-binding proteins, such as follistatin, and those
binding competitively to activin/TGFb ActIIb recep-
tors, are not yet available for human use [19, 36].
Studies of animal models from various laboratories
differ greatly as to whether the inhibition of myo-
statin is beneficial or detrimental [1, 15, 36].
Accordingly, the intention to inhibit myostatin ther-
apeutically in human muscle disorders must be con-
sidered circumspectly and with regard to whether it
is appropriate or not.
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